Development of a competitive ELISA for detecting antibodies to the peste des petits ruminants virus using a recombinant nucleobrotein

A competitive ELISA based on the reaction between a monoclonal antibody (mAb) and a recombinant nucleoprotein of the peste des petits ruminants virus (PPRV) was developed. This protein was obtained in large quantities from insect cells infected with a PPR nucleoprotein recombinant baculovirus (N-B). The competitive ELISA was compared with the virus neutralisation test (VNT) for detecting specific antibodies to PPRV in sheep and goats. The time consuming VNT is the only prescribed test that is capable of distinguishing between PPRV and the cross-reactive rinderpest virus (RPV). The competitive ELISA involves the simultaneous addition of the mAb and antibodies present in a positive serum, leading to competition for a specific epitope on the N-B. Optimum conditions were obtained by using serum samples which had positive or negative neutralising activity against PPRV Or RPV. A negative cut-off point was determined on PPRV-negative sera from RPV-vaccinated cattle. A threshold value of 48 per cent inhibition, calculated from the mean for this population plus 2·7 standard deviations, was used in routine testing. A total of 683 sera were analysed by the competitive ELISA and the VNT. A good correlation (r = 0·94) was observed between the titres obtained in the two tests, with 80 sera that were from laboratory sources. The agreement between the two tests was determined on 271 field sera (kappa = 0825). Their relative sensitivity (94·5 per cent) and specificity (99·4 per cent) were assessed on the 148 laboratory sera plus the 271 sera used for the determination of kappa. The durations of passive immunity in 23 goats, as determined by the VNT and the competitive ELISA, were 120 and 90 days, respectively, which indicates some differences between the anti-haemagglutinin and anti-N protein kinetics. The competitive ELISA is as sensitive and specific as the VNT, with the added advantage that it uses an antigen that is safe and can be produced in large quantities. © 1995.